As biologics, advanced therapies, and specialised injectable medicines continue to reshape the pharmaceutical landscape, the demand for agile and highly compliant sterile manufacturing partners has never been greater. In this Biopharma Boardr... Read more
As clinical development grows more complex and globally interconnected, biotech companies are under increasing pressure to build CRO partnerships that deliver more than operational support. In this Biopharma Boardroom Q&A, Greg Plunkett discusses... Read more
As healthcare shifts toward precision medicine and data-driven care, continuous biochemical monitoring is emerging as a transformative frontier in both clinical medicine and biopharma development. Profusa is at the forefro... Read more
Q1 2026 Group performance Comparable order intake growth 6% Group sales of EUR 3.9 billion, reflecting 4% increase in comparable sales Income from operations increased to EUR 241 million Adjusted EBITA margin increased 40 basis points t... Read more
Q1 2026 Group performance Comparable order intake growth 6% Group sales of EUR 3.9 billion, reflecting 4% increase in comparable sales Income from operations increased to EUR 241 million Adjusted EBITA margin increased 40 basis points t... Read more
Financial performance Q1 2026 reported sales increased by 32% at CER, positively impacted by a provision reversal related to the 340B Drug Pricing Program in the US. Q1 2026 adjusted sales, excluding the 340B provision reversal, decreased... Read more
Ceremonial groundbreaking kicks off the first construction phase Pharmaceutical service provider advances its expansion with a 50,000 sqm facility Strategic investments in the EU and US strengthen Vetter’s global footprint ... Read more
As clinical development grows more complex and globally interconnected, biotech companies are under increasing pressure to build CRO partnerships that deliver more than operational support. In this Biopharma Boardroom Q&A, Greg Plunkett discusses... Read more
© 2026 Biopharma Boardroom. All Rights Reserved.
